{"prompt": "['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Abbreviation or Specialist Term', 'Explanation', 'PET', 'positron emission tomography', 'PFS', 'progression-free survival', 'PFS1', 'PFS during SVdX treatment', 'PFS2', 'PFS on first post-SVd/Vd/SVdX treatment', 'PI', 'proteasome inhibitor', 'PK', 'pharmacokinetic(s)', 'POEMS', 'polyneuropathy, organomegaly, endocrinopathy, monoclonal', 'gammopathy, and skin changes', 'PP', 'per-protocol', 'PR', 'partial response', 'QIW', '4 times per week', 'CCI', 'QoL', 'quality of life', 'QW', 'once weekly', 'RBC', 'red blood cell', 'R-ISS', 'Revised International Staging System', 'RNA', 'ribonucleic acid', 'RRMM', 'relapsed or refractory multiple myeloma', 'SAE', 'serious adverse event', 'SAM', 'S-adenosylmethionine', 'SAP', 'statistical analysis plan', 'SC', 'subcutaneous(ly)', 'sCR', 'stringent complete response', 'SD', 'stable disease', 'Sd', 'selinexor plus low-dose dexamethasone', 'SdX', 'selinexor plus low-dose dexamethasone treatment after crossover', 'Sel', 'selinexor', 'SI', 'International System of Units', 'SINE', 'selective inhibitor of nuclear export', 'SOC', 'system organ class', 'SPd', 'selinexor plus pomalidomide plus low-dose dexamethasone', 'SPD', 'sum of the products of the maximal perpendicular diameters of', 'measured lesions', 'Confidential', 'Page 15', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', 'Abbreviation or Specialist Term', 'Explanation', 'SPEP', 'serum protein electrophoresis', 'Study Manual', 'Manual for the study site that may include any of the following:', 'Laboratory Manual, Pharmacy Manual, Investigator Binder,', 'Case Report Form Guidelines, Interactive Response', 'Technologies User Guidelines, and any other site materials that', 'are generated for the study such as Imaging Guidelines, etc.', 'SUSAR', 'suspected unexpected serious adverse reaction', 'SVd', 'selinexor plus bortezomib plus low-dose dexamethasone', 'SVdX', 'SVd treatment after crossover', 'TEAE', 'treatment-emergent adverse event', 't1/2', 'elimination (terminal) half-life', 'TLS', 'tumor lysis syndrome', 'tmax', 'time to peak plasma concentration', 'TSP', 'tumor suppressor protein', 'TTNT', 'time-to-next-treatment', 'TTR', 'time to response', 'ULN', 'upper limit of normal', 'UPEP', 'urine protein electrophoresis', 'URL', 'uniform resource locator', 'USA', 'United States of America', 'Vd', 'bortezomib plus low-dose dexamethasone', 'VGPR', 'very good partial response', 'WBC', 'white blood cell', 'X', 'visit for in-clinic dosing and multiple myeloma disease', 'assessment', 'XPO1', 'exportin 1', 'Confidential', 'Page 16', 'Version 4.0']['Investigational Product (KPT-330)', 'Karyopharm Therapeutics Inc.', 'Clinical Study Protocol: KCP-330-023', '17 August 2018', '2.', 'PROTOCOL SYNOPSIS', 'Sponsor:', 'Investigational Product:', 'Study Phase:', 'Karyopharm Therapeutics Inc.', 'Selinexor (KPT-330)', 'Phase 3', 'Title of Study:', 'A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone', '(SVd) versus Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple', 'Myeloma (RRMM)', 'Study Name:', 'BOSTON: Bortezomib, Selinexor, and Dexamethasone in Patients with Multiple Myeloma', 'Protocol Number: KCP-330-023', 'Indication: Relapsed or refractory multiple myeloma (RRMM)', 'Overall Study Design: This Phase 3, 2-arm, randomized, active comparator-controlled, open-label,', 'multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the', 'safety of selinexor plus bortezomib (Velcade or generic equivalent) plus low-dose dexamethasone', '(SVd) versus bortezomib plus low-dose dexamethasone (Vd) in adult patients with RRMM who have', 'received 1 to 3 prior anti-multiple myeloma (MM) regimens. After progressive disease (PD) is', 'confirmed by the Independent Review Committee (IRC), patients in the Vd Arm may cross over to a', 'regimen that includes selinexor: 1) SVd treatment (SVdX) for patients who are able to tolerate continued', 'bortezomib, or 2) selinexor and dexamethasone treatment (SdX) for patients who have significant', 'tolerability issues with bortezomib. Patients who cross over will be referred to as SVdX patients or SdX', 'patients, respectively.', 'The study overview is presented in the figure below.', '*Patients progressing on Vd', 'may cross over to SVdX', 'treatment if they are able to', 'tolerate continued', 'lortezomib-Dexamethasone (Vd*) (n=182)', 'bortezomib or to SdX if they', 'have significant tolerability', '-', '(~30%', '(~22', 'issues with bortezomib,', '(~33 months)', 'PFS', 'months)', 'following IRC-confirmed PD.', 'events)', 'Selinexor-Bortezomib-Dexamethasone (SVd) (n=182)', 'I', '1st', '2nd', 'PFS Primary', 'PFS IA', 'PFS IA', 'Analysis', '1st IA after ~30% PFS events for possible sample size re-estimation', '2nd IA after ~75% PFS events for futility or superiority', 'PFS primary analysis (~33 months after first patient is randomized)', 'Abbreviations: IA = interim analysis; IRC = Independent Review Committee; ITT = intent-to-treat; PD = progressive disease;', 'PFS = progression-free survival; SdX= = selinexor plus low-dose dexamethasone treatment after crossover; SVd = selinexor plus', 'bortezomib plus low-dose dexamethasone; SVdX = SVd treatment after crossover; Vd = bortezomib plus low-dose', 'dexamethasone.', 'Confidential', 'Page 17', 'Version 4.0']\n\n###\n\n", "completion": "END"}